STOCK TITAN

Biodesix, Inc. - BDSX STOCK NEWS

Welcome to our dedicated page for Biodesix news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix stock.

Biodesix, Inc. (BDSX) is a trailblazing diagnostic solutions company specialized in the development and commercialization of blood-based molecular diagnostic tests. These tests advance the standard of care in oncology by providing invaluable data to help patients and their doctors make more informed decisions based on a patient's unique molecular profile. This approach is at the heart of precision medicine, aiming to provide the right treatment to the right patient at the right time.

The company is particularly focused on lung disease and operates in a single segment dedicated to providing diagnostic testing services. Biodesix partners with pharmaceutical companies to develop and commercialize diagnostic tests that accelerate drug development pipelines and bring effective therapies to the market.

Among its notable products are two commercialized tests, VeriStrat® and GeneStrat™, which offer rapid results within 72 hours and do not require tissue samples. These tests enable quicker and more precise treatment decisions, facilitating optimal patient care.

Biodesix's revenue streams come from two primary sources: providing diagnostic testing services related to blood-based lung and COVID-19 tests, and offering biopharmaceutical companies services for diagnostic research, clinical trial testing, and companion diagnostics development. These services are generally performed outside the clinical setting and are governed by individual contracts with third parties.

Recently, Biodesix has been in the news for various significant developments. The latest updates highlight the company's ongoing projects, partnerships, and achievements in the diagnostic field. Stay tuned for more updates as Biodesix continues to innovate in precision medicine and diagnostic solutions.

Rhea-AI Summary

Biodesix (Nasdaq: BDSX) has been named to Inc. Magazine’s 2024 Best Workplaces list. The accolade results from an in-depth, data-driven process identifying American companies with exceptional workplace cultures. Biodesix, a diagnostic solutions leader, was one of 543 honorees selected from thousands of submissions. The recognition follows a comprehensive employee survey by Quantum Workplace, focusing on management effectiveness, perks, recognition, and overall culture. Founded in 2006, Biodesix reported high double-digit revenue growth and a 93% employee engagement score. CEO Scott Hutton emphasized the company's commitment to a culture of excellence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Biodesix, a diagnostic solutions company specializing in lung disease, has announced its participation in two investor conferences in June 2024. CEO Scott Hutton will present at the William Blair 44th Annual Growth Stock Conference on June 4 in Chicago, IL, at 10:40 AM CT. He will also present at the Jefferies Global Healthcare Conference on June 6 in New York, NY, at 8:30 AM ET. Both presentations will be webcast live and available for replay in the Investors section of Biodesix's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Biodesix announced that it will present new data on the Nodify XL2 test at the 2024 ATS International Conference. The data focuses on the test's ability to identify benign lung nodules in patients with emphysema. The presentation will review a subgroup analysis from the ORACLE study involving 280 patients, demonstrating high negative predictive value of the test, helping to rule out lung cancer irrespective of emphysema status. Dr. Arthur Romero from UNLV will present the findings, suggesting that the test can help avoid unnecessary procedures, thereby allowing timely emphysema treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Biodesix, Inc. (Nasdaq: BDSX) announced first-quarter 2024 results showcasing total revenue of $14.8 million, a 64% year-over-year increase, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume. The company raised $55 million in gross proceeds from a public offering. Biodesix reported a record quarterly gross profit margin of 79% and a Net Loss improvement of 27%. The company aims to reach profitability by growing revenue and maintaining cost discipline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Biodesix, Inc. (Nasdaq: BDSX) will participate in the 2024 RBCCM Global Healthcare Conference, with CEO Scott Hutton hosting investor meetings. The conference will take place from May 14-15, 2024, in New York, NY. The presentation will be webcast live and available for replay on Biodesix's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
-
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) will report its first-quarter 2024 financial results on May 8, 2024. The company, specializing in lung disease diagnostics, will host a conference call and webcast to discuss the results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
conferences earnings
Rhea-AI Summary
Biodesix, Inc. (BDSX) presented new data at the AACR Annual Meeting 2024 showcasing advancements in liquid biopsy technologies for detecting cell-free DNA and the importance of rapid turnaround time in identifying actionable tumor mutations in a real-world clinical setting. The studies included a presentation on single cell and cell-free nucleic acid analyses using a new droplet digital PCR system, as well as real-world assessment of turnaround time for variant testing in NSCLC. An exploratory analysis from the FLAURA2 clinical study sponsored by AstraZeneca was also presented, focusing on the prognostic and predictive nature of EGFR mutations in patients with EGFR-mutated advanced NSCLC receiving first-line osimertinib treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
conferences
-
Rhea-AI Summary
Biodesix, Inc. (BDSX) announces the pricing of its underwritten offering of common stock and concurrent private placement, expecting gross proceeds of $55.0 million. The company plans to convert Series A Non-Voting Convertible Preferred Stock to common stock upon stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
-
Rhea-AI Summary
Biodesix, Inc. (BDSX) has signed a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center to develop diagnostic tests for cancer treatment. The collaboration aims to create oncology biomarker assays utilizing Biodesix's genomics, proteomics, and data mining capabilities, along with Bio-Rad's digital PCR assay technology. This partnership marks a significant milestone for Biodesix in the field of oncology diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
none
Rhea-AI Summary
Biodesix, Inc. (BDSX) reports impressive financial and operational results for the fourth quarter and fiscal year 2023, showcasing significant growth in Lung Diagnostic test volume, gross profit margin improvement, and strong revenue guidance for 2024. The company achieved a 65% increase in Lung Diagnostic test volume in FY2023, with a 77% gross profit margin in Q4 2023. Total revenue for Q4 2023 was $14.7 million, representing a 52% increase year-over-year. Biodesix anticipates generating $65 to $68 million in total revenue in 2024, indicating a 32% to 39% growth rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags

FAQ

What does Biodesix, Inc. specialize in?

Biodesix specializes in blood-based molecular diagnostic tests that advance care in oncology, focusing primarily on lung disease.

What are some of Biodesix's key products?

Biodesix's key products include VeriStrat® and GeneStrat™, which provide rapid test results within 72 hours without needing tissue samples.

How does Biodesix contribute to precision medicine?

Biodesix contributes to precision medicine by helping physicians provide the right treatment to the right patient at the right time, based on the patient's unique molecular profile.

What services does Biodesix provide to biopharmaceutical companies?

Biodesix provides diagnostic research, clinical trial testing, and the development and commercialization of companion diagnostics to biopharmaceutical companies.

What are Biodesix's primary revenue sources?

Biodesix's revenue mainly comes from providing diagnostic testing services for blood-based lung and COVID-19 tests and offering services to biopharmaceutical companies.

How quickly can Biodesix's tests provide results?

Biodesix's tests, such as VeriStrat® and GeneStrat™, offer results within 72 hours.

Does Biodesix require tissue samples for its tests?

No, Biodesix's tests do not require tissue samples.

What recent achievements has Biodesix made?

Biodesix has recently been in the news for its ongoing projects, partnerships, and significant advancements in diagnostic solutions.

Is Biodesix focused solely on oncology diagnostics?

While Biodesix focuses heavily on oncology diagnostics, it also provides COVID-19 testing services.

What is the ticker symbol for Biodesix, Inc. on the stock market?

The ticker symbol for Biodesix, Inc. is BDSX.

Biodesix, Inc.

Nasdaq:BDSX

BDSX Rankings

BDSX Stock Data

202.99M
114.69M
62.91%
19.67%
0.2%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
BOULDER